Moreover, the indication that the CCL21+ICAM1 SIN enhances expansion of T-cells, render the SIN approach highly suitable for TIL therapy, in which high numbers of cells are a favorable prognostic indicators for successful therapy in different tumor types (43–45) and specifically in foretelling the success of checkpoint therapies (46). This evidence concerns the gene CCL21 and neoplasm.